The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit - PubMed (original) (raw)
Clinical Trial
doi: 10.1038/sj.bmt.1705591. Epub 2007 Feb 26.
Affiliations
- PMID: 17322937
- DOI: 10.1038/sj.bmt.1705591
Clinical Trial
The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit
M Craig et al. Bone Marrow Transplant. 2007 Apr.
Abstract
Febrile neutropenia is an expected complication during treatment of aggressive hematological malignancies and hematopoietic cell transplantation. We conducted a prospective cohort trial to determine the effects and safety of prophylactic fluoroquinolone administration, and rotation of empiric antibiotics for neutropenic fever in this patient population. From March 2002 through 2004, patients were treated with prophylactic levofloxacin during prolonged neutropenia, and a cycling schedule of empiric antibiotic therapy for neutropenic fever was initiated. The rates of bacteremia, resistance and complications were compared to a retrospective cohort of previously treated patients. The rate of gram-negative bacteremia decreased after the initiation of prophylactic levofloxacin (4.7 vs 1.8 episodes/1000 patient days, P<0.05). Gram-positive bacteremia rates remained unchanged, but more isolates of Enterococcus faecium were resistant to vancomycin after the intervention began. Resistance to the antibiotic agents used in the rotation did not emerge. There was no change in mortality during the intervention period. A prophylactic and cycling antibiotic schedule was successfully implemented on a hematological malignancy and hematopoietic cell transplant unit. gram-negative bacteremia was significantly decreased, without emergence of resistance. Concerns with Gram-positive resistance will require further observation.
Similar articles
- Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR. Cumpston A, et al. Transpl Infect Dis. 2013 Apr;15(2):142-9. doi: 10.1111/tid.12035. Epub 2012 Dec 20. Transpl Infect Dis. 2013. PMID: 23279656 - Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S, Kern WV, Sigge A, Döhner H, Marre R, Kern P, von Baum H. Reuter S, et al. Clin Infect Dis. 2005 Apr 15;40(8):1087-93. doi: 10.1086/428732. Epub 2005 Mar 11. Clin Infect Dis. 2005. PMID: 15791505 Clinical Trial. - Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L, Brown M, Sasadeusz J, MacGregor L, Grigg AP. Chee L, et al. J Infect. 2008 Apr;56(4):227-33. doi: 10.1016/j.jinf.2008.01.046. Epub 2008 Mar 17. J Infect. 2008. PMID: 18342947 - Bloodstream infections in cancer patients with febrile neutropenia.
Feld R. Feld R. Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3. doi: 10.1016/j.ijantimicag.2008.06.017. Epub 2008 Sep 7. Int J Antimicrob Agents. 2008. PMID: 18778919 Review. - Management of bacteremia in patients undergoing hematopoietic stem cell transplantation.
Castagnola E, Faraci M. Castagnola E, et al. Expert Rev Anti Infect Ther. 2009 Jun;7(5):607-21. doi: 10.1586/eri.09.35. Expert Rev Anti Infect Ther. 2009. PMID: 19485800 Review.
Cited by
- Modelling and Simulation of the Effect of Targeted Decolonisation on Incidence of Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections in Haematological Patients.
Döbele S, Mazzaferri F, Dichter T, de Boer G, Friedrich A, Tacconelli E. Döbele S, et al. Infect Dis Ther. 2022 Feb;11(1):129-143. doi: 10.1007/s40121-021-00550-3. Epub 2021 Oct 19. Infect Dis Ther. 2022. PMID: 34665434 Free PMC article. - Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.
Chong Y, Shimoda S, Yakushiji H, Ito Y, Aoki T, Miyamoto T, Kamimura T, Shimono N, Akashi K. Chong Y, et al. PLoS One. 2014 Jan 22;9(1):e85210. doi: 10.1371/journal.pone.0085210. eCollection 2014. PLoS One. 2014. PMID: 24465506 Free PMC article. - Results of Levofloxacin Prophylaxis Timing in Autologous and Allogeneic Stem Cell Transplantation: A Retrospective Cohort Study.
Özkan SG, Safaei S, Kimiaei A, Çınar Y, Sönmezoğlu M, Özkan HA. Özkan SG, et al. Cureus. 2024 Apr 4;16(4):e57598. doi: 10.7759/cureus.57598. eCollection 2024 Apr. Cureus. 2024. PMID: 38707020 Free PMC article. - Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.
Chong Y, Shimoda S, Miyake N, Aoki T, Ito Y, Kamimura T, Shimono N. Chong Y, et al. Infect Drug Resist. 2017 Jun 27;10:193-199. doi: 10.2147/IDR.S133333. eCollection 2017. Infect Drug Resist. 2017. PMID: 28721078 Free PMC article. - Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi K. Chong Y, et al. PLoS One. 2013;8(1):e54190. doi: 10.1371/journal.pone.0054190. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372683 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources